Drug
LB-102
LB-102 is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
2
40%
Ph phase_3
1
20%
Phase Distribution
2
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(3)
Detailed Status
Completed3
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Trials by Status
not_yet_recruiting120%
recruiting120%
completed360%
Recent Activity
1 active trials
Showing 5 of 5
not_yet_recruitingphase_3
52-week Open Label Safety-Tolerability Study
NCT07369154
recruitingphase_2
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT07494305
completedphase_2
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT06179108
completedphase_1
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
NCT04588129
completedphase_1
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
NCT04187560
Clinical Trials (5)
Showing 5 of 5 trials
NCT07369154Phase 3
52-week Open Label Safety-Tolerability Study
NCT07494305Phase 2
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT06179108Phase 2
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT04588129Phase 1
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
NCT04187560Phase 1
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5